Did You Know...
...that several people are credited with the invention of the flush toilet? Most people have heard of Thomas Crapper (1837-1910), the sanitary engineer who invented the valve-and-siphon arrangement that made the modern toilet possible. Another claimant to "the throne" was British inventor Alexander Cumming who patented a toilet in 1775. Then there's a nameless Minoan (a native of ancient Crete) who lived 4,000 years ago who supposedly was ahead of his time and created the first flush toilet!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 6548477 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. Th... | 04/15/2003 |
| 6545123 | Synthetic glycosulfopeptides and methods of synthesis thereof A new class of synthetic glycosulfopeptides (GSPs) which have one or more sulfated tyrosine residues and a glycan linked to the peptide, the glycan preferably including a sialyl Lewisx group or a sialyl Lewisa group. In a preferred v... | 04/08/2003 |
| 6545125 | Compounds with antitumor activity Compounds of the formula (1) or tautomers, stereoisomers or optical isomers thereof of the formula X--L--Y wherein X is paclitaxel or its derivative; L represents a linker having at least one functional group; and Y represents ##STR1##... | 04/08/2003 |
| 6541451 | Streptogramin derivatives, their preparation and compositions containing them B-Group streptogramin compounds of formula (I): ##STR1## are useful as antimicrobial agents, optionally combined with at least one A-group streptogramin compound.... | 04/01/2003 |
| 6534290 | Methods for production of growth-promoting proteins and peptides for kidney epithelial cells Novel growth peptides derived from protein factors having molecular weights of about 22 and 45 kDa stimulate mitogenic activity of epithelial, but not fibroblastic cells, in particular, kidney epithelial cells. A source of the factors is scrape-wounded ki... | 03/18/2003 |
| 6534478 | Cyclic azapeptides with angiogenic effect Compounds of the formula I cyclo-(aArg-aGly-aAsp-aX-aY) I in which aArg, aGly, aAsp, aX and aY have the meanings indicated in claim 1, and their salts, can be used as integrin inhibitors, in particular for the prophylaxis and treatment of diseases of the circ... | 03/18/2003 |
| 6531578 | Immunoassay method employing monoclonal antibody reactive to human iNOS A panel of monoclonal antibodies recognizing and binding to human inducible nitric oxide synthase (iNOS or type II iNOS) enzyme have been developed. The monoclonal antibodies may also be employed in an assay to detect the presence and/or quantitate the am... | 03/11/2003 |
| 6531446 | Peptides having biological activity The present invention relates to peptides that are more potent than or equally potent as the conventional antimicrobial peptides and has strong antimicrobial activities at high salt concentration.... | 03/11/2003 |
| 6528487 | Peptide inhibitors of inflammation mediated by selectins Peptides derived from three regions of the lectin domain of GMP-140 and the related selectins, ELAM-1 and the lymphocyte homing receptor, have seen found to inhibit neutrophil adhesion to GMP-140. These and additional peptides have been synthesized, havin... | 03/04/2003 |
| 6521599 | Stable pharmaceutical formulation for intravenous or intramuscular administration of active peptide compounds A stable pharmaceutical formulation for intravenous or intramuscular administration of Octreotide, which is characterized in that the vehicle for injection of the peptide or pharmaceutically acceptable salts thereof contains glycine in concentrations rang... | 02/18/2003 |
| 6518242 | Derivatives of glycopeptide antibacterial agents Novel antibacterial agents that act as multibinding agents are disclosed. The compounds of the invention comprise from 2-10 ligands covalently connected, each of said ligands being capable of binding to a transglycosylase enzyme substrate thereby modulati... | 02/11/2003 |
| 6518246 | Pharmaceutical composition and method for the treatment of neoplastic cells A pharmaceutical composition and method, for treating human or non-human neoplastic disorders, e.g. colorectal disorders, comprising the administration of pharmaceutically effective amounts of galanin, octreotide and serotonin in a pharmaceutically accept... | 02/11/2003 |
| 6518397 | Pharmaceuticals for modulating hormone responsiveness This invention relates to isolated and purified proteins, such as calreticulin and mimetics and inhibitors of calreticulin, for a novel use of modulating hormone responsiveness. These proteins are useful in gene therapy and in manufacturing pharmaceutical... | 02/11/2003 |
| 6514701 | Antimicrobial peptides and methods of use thereof Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitutio... | 02/04/2003 |
| 6511961 | Cyclic peptides and medicinal use thereof Novel cyclic peptides having VLA-4 adhesion inhibiting activity, and their application as therapeutic agents for inflammatory disease, for example allergic inflammatory disease, or hepatitis. Cyclic peptides represented by formula (I) ##STR1## where ... | 01/28/2003 |
| 6509318 | TGF-B inhibitors and methods A family of small peptides have been found to be inhibitory to TGF-ଲ activity, and preferably have the primary structure of Formula I: AA1 -AA2 -AA3 -Pro-D-Glu-Ala FORMULA I wherein AA1 is leucine, phenylalanine, &... | 01/21/2003 |
| 6506731 | Elastin peptide analogs and methods of using same The present invention is directed to a composition which is used to enhance the elasticity and/or appearance of tissue. Specifically, the present invention is directed to a composition formulated from peptides having low molecular weights and which substa... | 01/14/2003 |
| 6503881 | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics Compositions and methods for treating infections, especially bacterial infections, are provided. Indolicidin peptide analogues containing at least two basic amino acids are prepared. The analogues are administered as modified peptides, preferably containi... | 01/07/2003 |
| 6500798 | Use of colostrinin, constituent peptides thereof, and analogs thereof, as oxidative stress regulators The present invention provides methods that utilize compositions containing colostrinin, an constituent peptide thereof, an active analog thereof, and combinations thereof, as an oxidative stress regulator.... | 12/31/2002 |
| 6498027 | Targeted delivery through a cationic amino acid transporter The invention relates to the targeted delivery of substances to cells. The invention provides a virus-like particle or gene delivery vehicle provided with a ligand capable of binding to a human amino acid transporter. Provided are, for example, ligands th... | 12/24/2002 |
| 6495663 | Method and composition for enhancing transport across biological membranes Methods and compositions for transporting drugs and macromolecules across biological membranes are disclosed. In one embodiment, the invention includes a method for enhancing transport of a selected compound across a biological membrane, wherein a biologi... | 12/17/2002 |
| 6492489 | Synthetic hypusine peptides The invention relates to novel peptides synthesized according a method utilizing the hypusine reagent: ##STR1## wherein: Q1 Q2 and Q3 may be the same or different and are amino protective groups, provided that Q3 | 12/10/2002 |
| 6492491 | Method of making hypusine peptides The invention relates to novel peptides synthesized according a method utilizing the hypusine reagent: ##STR1## wherein: Q1 Q2 and Q3 may be the same or different and are amino protective groups, provided that Q3 | 12/10/2002 |
| 6489446 | Self-aligning peptides modeled on human elastin and other fibrous proteins A polypeptide is provided that has a secondary structure characterized by at least three beta-sheet/beta-turn structures, and that is not a naturally occurring fibrous protein. Such polypeptides, illustrated by one modeled on elastin, are useful in prosth... | 12/03/2002 |
| 6482919 | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell The present invention provides novel soluble CTLA4Ig molecules having modified Ig domains.... | 11/19/2002 |
| 6476188 | Clock gene and methods of use thereof The present invention discloses the identity of the first enzyme that has been demonstrated to be involved in maintaining circadian rhythms. This enzyme, the Drosophila DOUBLETIME protein is also shown to be an ortholog of human casein kinase-1&3xb5;. In ... | 11/05/2002 |
| 6475775 | PARG, a GTPase activating protein which interacts with PTPL1 The invention describes nucleic acids encoding the PARG protein, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such nucleic acids, and antibodies relating thereto. Methods... | 11/05/2002 |
| 6475988 | Methods to increase white blood cell survival after chemotherapy The present invention provides improved methods, kits, and pharmaceutical compositions for increasing white blood cell survival following chemotherapy, and mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood, comprising the ad... | 11/05/2002 |
| 6472504 | Inhibitors of collagen assembly The invention relates to peptides and peptidomimetics which inhibit assembly of human type I collagen. Methods of identifying such peptides and peptidomimetics are also included in the invention.... | 10/29/2002 |
| 6472507 | Carrier based drug delivery system The present invention relates to a novel drug delivery system of use in the improved delivery of drug therapeutic agents into target cells. The system comprises a drug moiety linked to a carrier moiety wherein the carrier moiety comprises a homeobox pepti... | 10/29/2002 |
| 6469137 | Myelopeptides and their therapeutic use The present invention pertains to peptides comprising 4 to 10 amino acids including X1 -Pro, Pro-X2 or X1 -Pro-X2, wherein X1 and X2 are independently selected from Lys, Arg, His, Asp, Glu,... | 10/22/2002 |
| 6468969 | Inhibition of HIV-1 replication using d-amino acid peptides The Tat-inhibitory polypeptide derivatives of the formula I D-Cys-D-Phe-D-Thr-D-Thr-D-Lys-D-Ala-D-Leu-D-Gly-D-Ile-D-Ser-D-Tyr-D-Gly-D-A rg-D-Lys-D-Lys-D-Arg-D-Arg-D-Gln-D-Arg-D-Arg-D-Arg-D-Pro-D-Pro-D-Gln-D-Gly- D-Ser-D-Gln-D-Thr-D-His-D-Gln-D-Val-D-Ser-D-Leu-D-... | 10/22/2002 |
| 6465613 | Hydrophilic somatostatin analogs The invention features novel somatostatin analogs that may be readily labeled with toxic or non-toxic detectable labels. These unlabeled and labeled analogs are useful for specifically targeting somatostatin receptor bearing cells, in particular neoplasti... | 10/15/2002 |
| 6465253 | Vectors and methods for gene transfer to cells The present invention provides a chimeric adenovirus coat protein, which differs from the wild-type coat protein by the introduction of a nonnative amino acid sequence. Such a chimeric adenovirus coat protein according to the invention is able to direct e... | 10/15/2002 |
| 6465432 | Isolated antioxidant peptides form casein and methods for preparing, isolating, and identifying antioxidant peptides The current invention provides antioxidative peptide fractions. The invention includes antioxidative peptides of casein having sequences of SEQ ID NOS:1-5. The invention includes methods for making or generating the peptides, isolated nucleic acids encodi... | 10/15/2002 |
| 6462171 | Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits Novel peptides capable of interacting with a hydrophobic ଲ-sheet forming cluster of amino acid residues on a protein or peptide for amyloid or amyloid-like deposit formation inhibit and structurally block the abnormal folding of proteins and peptide... | 10/08/2002 |
| 6461611 | Agents for the prevention of damages caused by stress conditions Pharmaceutical compositions for the treatment of a decrease in the levels of protease activated receptor (PAR) mRNA caused by a lack or decrease of oxygen level and/or a lack or decrease of blood flow including pharmaceutically acceptable carriers and act... | 10/08/2002 |
| 6462173 | Inhibitors of phosphoserine and phosphothreonine-proline-specific isomerases Inhibitors of phosphoserine- or posphothreonine-specific peptidyl prolyl isomerases are described. Such inhibitors include molecules that mimic the structure and conformation of the pSer/pThr-Pro peptide moiety of the isomerase substrate when the substrat... | 10/08/2002 |
| 6462180 | Method of preparing -1 proteinase inhibitor Purification of -1 proteinase inhibitor (-1 PI) from aqueous solutions, such as human plasma, is accomplished by precipitation of contaminating proteins from the aqueous solution, followed by dilution of the solution to adjust its conductivi... | 10/08/2002 |
| 6458925 | Peptide antagonists of zonulin and methods for use of the same Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the zonula occludens receptor, yet do not physiologically modulate the opening of mammalian tight junctions.... | 10/01/2002 |
